BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A. Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis. J Crohns Colitis. 2016;10:575-581. [PMID: 26738756 DOI: 10.1093/ecco-jcc/jjv241] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
2 Van den Berghe N, Gils A, Thomas D. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted? Clin Pharmacol Ther 2019;106:945-54. [PMID: 31420861 DOI: 10.1002/cpt.1609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
3 Orlandini B, Dragoni G, Variola A, Massella A, Bagnoli S, Campi R, Rogai F. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers. J Dig Dis 2018;19:468-74. [PMID: 30039533 DOI: 10.1111/1751-2980.12648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther 2020;42:157-174.e4. [PMID: 31982148 DOI: 10.1016/j.clinthera.2019.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Berger A, Duru G, de Vries A, Marini JC, Aoucheta D, Cornillie F, Nancey S, Detrez I, Gils A, Roblin X, Paul S. Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study. Therapeutic Drug Monitoring 2019;41:459-66. [DOI: 10.1097/ftd.0000000000000629] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
6 Tursi A, Allegretta L, Della Valle N, Hadad Y, Penna A, Pranzo G, Ricciardelli C, Paiano P, Picchio M. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis. Clin Res Hepatol Gastroenterol 2016;40:e61-3. [PMID: 27297910 DOI: 10.1016/j.clinre.2016.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Harzallah I, Rigaill J, Williet N, Paul S, Roblin X. Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol 2017;10:89-100. [PMID: 28286562 DOI: 10.1177/1756283X16676194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Stefanovic S, Detrez I, Compernolle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, Ferrante M, Gils A, Drobne D. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol 2021;33:54-61. [PMID: 32804854 DOI: 10.1097/MEG.0000000000001843] [Reference Citation Analysis]
9 Bressler B, Williamson M, Sattin B, Camacho F, Steinhart AH. Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. J Can Assoc Gastroenterol. 2018;1:129-134. [PMID: 31294354 DOI: 10.1093/jcag/gwy019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
11 Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101-111. [PMID: 29042821 DOI: 10.2147/cpaa.s138414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
12 Alhalabi M, Eddin KA, Cheha K, Abbas A. Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report. Medicine (Baltimore) 2021;100:e27283. [PMID: 34559136 DOI: 10.1097/MD.0000000000027283] [Reference Citation Analysis]
13 Strik AS, Berends SE, Löwenberg M. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward? Expert Rev Clin Pharmacol 2019;12:885-91. [PMID: 31305158 DOI: 10.1080/17512433.2019.1642745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Detrez I, Gils A. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis 2017;11:1-2. [PMID: 27481879 DOI: 10.1093/ecco-jcc/jjw141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Strik AS, Berends SE, Mathôt RA, D'Haens GR, Löwenberg M. Golimumab for moderate to severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2017;11:401-6. [PMID: 28276288 DOI: 10.1080/17474124.2017.1303376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 29.0] [Reference Citation Analysis]
17 Philip G, Cornillie F, Adedokun JO, Melsheimer R, Rutgeerts P, Colombel JF, Marano C. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. J Crohns Colitis 2019;13:1257-64. [PMID: 30847474 DOI: 10.1093/ecco-jcc/jjz052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
18 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Spencer EA, Dubinsky MC. Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Pediatric Clinics of North America 2017;64:1309-26. [DOI: 10.1016/j.pcl.2017.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Sousa HT, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Cornillie F, Lopes J, Carneiro F; Portuguese IBD Group [GEDII]. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. Journal of Crohn's and Colitis 2019;13:1387-93. [DOI: 10.1093/ecco-jcc/jjz071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
21 Danese S, Fiorino G, Peyrin-biroulet L. Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:1280-1290.e1. [DOI: 10.1016/j.cgh.2020.01.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
22 Van den Berghe N, Truffot A, Peeters M, Compernolle G, Brouwers E, Soenen R, Grine L, Gils A, Imbrechts M. Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis. J Pharm Biomed Anal 2020;189:113433. [PMID: 32615342 DOI: 10.1016/j.jpba.2020.113433] [Reference Citation Analysis]
23 Detrez I, Brouwers E, Peeters M, Geukens N, de Vlam K, Gils A. Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept. J I 2016;196:2879-84. [DOI: 10.4049/jimmunol.1502195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Berends SE, Strik AS, Jansen JM, de Boer NK, van Egmond PS, Brandse JF, Mathôt RA, D’haens GR, Löwenberg M. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scandinavian Journal of Gastroenterology 2019;54:700-6. [DOI: 10.1080/00365521.2019.1619828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
25 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
26 Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet 2019;58:15-37. [PMID: 29752633 DOI: 10.1007/s40262-018-0676-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
27 Raja TW, Veeramuthu D, Savarimuthu I, Al-Dhabi NA. Current Trends in the Treatment of Systemic Lupus Erythematosus. Curr Pharm Des 2020;26:2602-9. [PMID: 32066358 DOI: 10.2174/1381612826666200211122633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
28 Samaan MA, Pavlidis P, Digby-Bell J, Johnston EL, Dhillon A, Paramsothy R, Akintimehin AO, Medcalf L, Chung-Faye G, DuBois P, Koumoutsos I, Powell N, Anderson SHC, Sanderson J, Hayee BH, Irving PM. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2018;9:221-231. [PMID: 30047549 DOI: 10.1136/flgastro-2017-100895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
29 Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017;23:1510-1515. [PMID: 28816757 DOI: 10.1097/mib.0000000000001231] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
30 Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther 2017;17:879-86. [PMID: 28472597 DOI: 10.1080/14712598.2017.1327576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
31 Bossuyt P, Baert F, D’heygere F, Nakad A, Reenaers C, Fontaine F, Franchimont D, Dewit O, Van Hootegem P, Vanden Branden S, Lambrecht G, Ferrante M, Hindryckx P, Macken E, Caenepeel P, Vijverman A, Suray ND, Dutré J, Louis E, Coenegracths J; Belgian IBD Research and Development Group. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflammatory Bowel Diseases 2019;25:156-62. [DOI: 10.1093/ibd/izy219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
32 Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017;11:35-46. [PMID: 27440869 DOI: 10.1093/ecco-jcc/jjw133] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 11.3] [Reference Citation Analysis]
33 Greener T, Boland K, Steinhart AH, Silverberg MS. The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s Disease. Journal of Crohn's and Colitis 2018;12:458-64. [DOI: 10.1093/ecco-jcc/jjx176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
34 Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine 2021;66:103329. [PMID: 33862588 DOI: 10.1016/j.ebiom.2021.103329] [Reference Citation Analysis]
35 Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 2017;153:835-857.e6. [PMID: 28774547 DOI: 10.1053/j.gastro.2017.07.031] [Cited by in Crossref: 149] [Cited by in F6Publishing: 124] [Article Influence: 29.8] [Reference Citation Analysis]
36 Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol 2019;12:1-9. [DOI: 10.1007/s12328-018-0906-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A. A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2019. [DOI: 10.1093/ibd/izz144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439 [PMID: 28058024 DOI: 10.3748/wjg.v22.i47.10432] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
39 Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2019;15:527-39. [PMID: 31177858 DOI: 10.1080/17425255.2019.1630378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
40 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
41 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?Curr Opin Gastroenterol. 2019;35:302-310. [PMID: 30973355 DOI: 10.1097/MOG.0000000000000536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
42 Samaan MA, Cunningham G, Tamilarasan AG, Beltran L, Pavlidis P, Ray S, Mawdsley J, Anderson SH, Sanderson JD, Arkir Z, Irving PM. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. Aliment Pharmacol Ther 2020;52:292-302. [PMID: 32506695 DOI: 10.1111/apt.15808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): where we stand today. Hum Vaccin Immunother 2021;17:1586-98. [PMID: 33369527 DOI: 10.1080/21645515.2020.1836919] [Reference Citation Analysis]
44 Olivera P, Danese S, Pouillon L, Bonovas S, Peyrin-Biroulet L. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Dig Liver Dis. 2019;51:327-334. [PMID: 30555013 DOI: 10.1016/j.dld.2018.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
45 Cunningham G, Samaan MA, Irving PM. Golimumab in the treatment of ulcerative colitis. Therap Adv Gastroenterol 2019;12:1756284818821266. [PMID: 30728858 DOI: 10.1177/1756284818821266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Detrez I, Van Stappen T, Martín Arranz MD, Papamichael K, Gils A. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. Ther Drug Monit 2017;39:344-9. [PMID: 28328760 DOI: 10.1097/FTD.0000000000000394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 4.3] [Reference Citation Analysis]
47 Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol 2021;56:1304-11. [PMID: 34415803 DOI: 10.1080/00365521.2021.1963466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Rocha C, Lago P, Fernandes S, Correia L, Portela F, Vieira AI, Patita M, Arroja B, Ministro P, Alves C, Dias CC, Magro F. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Therap Adv Gastroenterol 2020;13:1756284820965790. [PMID: 33281935 DOI: 10.1177/1756284820965790] [Reference Citation Analysis]
49 Vande Casteele N, Khanna R. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res 2017;34:1556-63. [PMID: 28374338 DOI: 10.1007/s11095-017-2150-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Perrig K, Krupka N, Jordi SBU, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka SR, Juillerat P, Burri E, Zimmermann D, Maillard MH, Sulz MC, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022;15:175628482210741. [DOI: 10.1177/17562848221074188] [Reference Citation Analysis]
51 Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.Expert Rev Clin Immunol. 2019;15:837-848. [PMID: 31180729 DOI: 10.1080/1744666X.2019.1630273] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
52 Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs 2017;77:363-77. [PMID: 28233275 DOI: 10.1007/s40265-017-0693-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
53 Boland K, Greener T, Kabakchiev B, Stempak J, Tessolini J, Li R, Soriano J, Croitoru K, Nguyen G, Steinhart AH, Weizman AV, Silverberg MS. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn’s Disease and Ulcerative Colitis Associated With Mucosal Healing. Inflammatory Bowel Diseases 2020;26:766-73. [DOI: 10.1093/ibd/izz199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Detrez I, Schops G, Lefrère J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, Ferrante M, Gils A. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. AAPS J 2018;21:10. [PMID: 30564993 DOI: 10.1208/s12248-018-0282-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Detrez I, Van Steen K, Segaert S, Gils A. The association between etanercept serum concentration and psoriasis severity is highly age-dependent. Clin Sci (Lond) 2017;131:1179-89. [PMID: 28420676 DOI: 10.1042/CS20170048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]